Neogenomics, Inc.
NEO
$6.45
-$0.155-2.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 689.19M | 672.36M | 660.57M | 644.12M | 628.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 689.19M | 672.36M | 660.57M | 644.12M | 628.25M |
| Cost of Revenue | 386.95M | 374.48M | 370.47M | 363.69M | 360.39M |
| Gross Profit | 302.24M | 297.88M | 290.10M | 280.43M | 267.86M |
| SG&A Expenses | 353.17M | 342.35M | 337.48M | 329.91M | 327.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 774.97M | 750.56M | 739.10M | 723.92M | 716.04M |
| Operating Income | -85.78M | -78.19M | -78.54M | -79.80M | -87.79M |
| Income Before Tax | -105.45M | -78.65M | -80.68M | -79.83M | -83.44M |
| Income Tax Expenses | -1.41M | -1.06M | -1.95M | -2.11M | -4.89M |
| Earnings from Continuing Operations | -104.04 | -77.59 | -78.73 | -77.73 | -78.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.04M | -77.59M | -78.73M | -77.73M | -78.55M |
| EBIT | -85.78M | -78.19M | -78.54M | -79.80M | -87.79M |
| EBITDA | -14.62M | -6.19M | -5.99M | -7.08M | -14.93M |
| EPS Basic | -0.82 | -0.61 | -0.62 | -0.62 | -0.62 |
| Normalized Basic EPS | -0.37 | -0.33 | -0.33 | -0.33 | -0.38 |
| EPS Diluted | -0.82 | -0.61 | -0.63 | -0.62 | -0.63 |
| Normalized Diluted EPS | -0.37 | -0.33 | -0.33 | -0.33 | -0.38 |
| Average Basic Shares Outstanding | 509.44M | 507.89M | 506.63M | 505.40M | 504.13M |
| Average Diluted Shares Outstanding | 509.44M | 507.89M | 506.63M | 505.40M | 504.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |